Apr 11 |
ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study
|
Apr 9 |
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)
|
Apr 6 |
ALX Oncology Holdings Inc (ALXO) Insider Sells Shares
|
Mar 10 |
Cantor sees strong year ahead for oncology M&A
|
Mar 8 |
Stifel downgrades ALX Oncology to hold, sees evorpacept as fully valued
|
Mar 8 |
ALX Oncology Has 'Elevated Valuation' - Analyst Downgrades Stock, Highlights Need For Development De-Risking Beyond Gastric Cancer
|
Mar 8 |
ALX Oncology Holdings Inc (ALXO) Reports Growth Amidst Increased R&D Spending
|
Mar 7 |
ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
|
Mar 5 |
ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting
|
Jan 3 |
ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|